Cases in Precision Oncology: Tumor Mutation Burden as a Biomarker in Solid Tumors
Tuesday, October 27, 2026
11:00am-12:00pm ET
1.0 AMA PRA Category 1 Credits™, P.A.C.E.® – Educational Credits Claim by November 30, 2026
This CME Case Series reflects the work of molecular tumor boards by featuring an interdisciplinary discussion of cases that are subject to comprehensive molecular characterization using a variety of advanced technologies. In this session, brain cancer pathology research lead,
Dr. Laveniya Satgunaseelan, Co-Lead of the Sydney Brain Tumour Bank at Chris O’Brien Lifehouse/Royal Prince Alfred Hospital and Staff Specialist in the Department of Neuropathology at Royal Prince Alfred Hospital, will explore how tumor mutation burden (TMB) has emerged as an important biomarker in solid tumor testing. This webinar will present the underlying principles of TMB, its role across different solid tumor types, and challenges in TMB interpretation, together with pertinent clinical examples.